Glycemia, Diabetes Status, and Cognition in Hispanic Adults Aged 55-64 Years

Psychosomatic Medicine

Volumn 77, Issue 6, 2015, Pages 653-663

  Luchsinger, José A ^a   Cabral, Rafi ^a   Eimicke, Joseph P ^c   Manly, Jennifer J ^b   Teresi, Jeanne ^a  

^a Department of Medicine   (United States)

^b Vagelos College of Physicians and Surgeons   (United States)

^c Research Division   (United States)

Author keywords

cognition; diabetes; glycemia; middle age; prediabetes

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; METFORMIN; SULFONYLUREA; THIAZOLIDINE DERIVATIVE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEMOGRAPHY; DEPRESSION; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DYSLIPIDEMIA; EDUCATIONAL STATUS; EXECUTIVE FUNCTION; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HISPANIC; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OUTCOME ASSESSMENT; PATIENT HEALTH QUESTIONNAIRE 9; PRIORITY JOURNAL; PSYCHOMETRY; RECALL; RECOGNITION; SHORT TERM MEMORY; SYSTOLIC BLOOD PRESSURE; TASK PERFORMANCE; VERBAL MEMORY; WAIST CIRCUMFERENCE; WAIST HIP RATIO; BLOOD; ETHNOLOGY; NEW YORK; PHYSIOLOGY;

COGNITION DISORDERS; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; EXECUTIVE FUNCTION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HISPANIC AMERICANS; HUMANS; MALE; MENTAL RECALL; MIDDLE AGED; NEW YORK CITY; PREDIABETIC STATE;

EID: 84936997291     PISSN: 00333174     EISSN: 15347796     Source Type: Journal    
DOI: 10.1097/PSY.0000000000000208     Document Type: Article

References (98)

1. Alzheimer's Association. 2014 Alzheimer's Disease Facts and Figures. Alzheimers Dement 2014; 10: e47-92.
2. Plassman BL, Langa KM, Fisher GG, Heeringa SG, Weir DR, Ofstedal MB, Burke JR, Hurd MD, Potter GG, Rodgers WL, Steffens DC, McArdle JJ, Willis RJ, Wallace RB,. Prevalence of Cognitive Impairment without Dementia in the United States. Ann Intern Med 2008; 148: 427-34.
3. NIH Consensus Development Conference Statement on Preventing Alzheimer's Disease and Cognitive Decline. NIH Consensus and State-of-the-Art Statements 2010; 27. Available at: http://consensus.nih.gov/2010/docs/alz/ALZ-Final-Statement.pdf. Accessed December 13, 2014.
4. Devanand D, Lee J, Luchsinger J, Manly J, Marder K, Mayeux R, Scarmeas N, Schupf N, Stern Y,. Lessons from epidemiologic research about risk factors, modifiers, and progression of late onset Alzheimer's disease in New York City at Columbia University Medical Center. J Alzheimers Dis 2013; 33: S447-55.
5. Biessels GJ, Strachan MWJ, Visseren FLJ, Kappelle LJ, Whitmer RA,. Dementia and cognitive decline in Type 2 diabetes and prediabetic stages: towards targeted interventions. Lancet Diabetes Endocrinol 2014; 2: 246-55.
6. CDC. Diabetes Public Health Resource: Diabetes Complications. Available at: http://www.cdc.gov/diabetes/statistics/complications-national.htm. 2014.
7. Roberts RO, Knopman DS, Przybelski SA, Mielke MM, Kantarci K, Preboske GM, Senjem ML, Pankratz VS, Geda YE, Boeve BF, Ivnik RJ, Rocca WA, Petersen RC, Jack CR,. Association of Type 2 diabetes with brain atrophy and cognitive impairment. Neurology 2014; 82: 1132-41.
8. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P,. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol 2006; 5: 64-74.
9. Rhee MK, Herrick K, Ziemer DC, Vaccarino V, Weintraub WS, Narayan KM, Kolm P, Twombly JG, Phillips LS,. Many Americans have pre-diabetes and should be considered for metformin therapy. Diabetes Care 2010; 33: 49-54.
10. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States. Atlanta, GA: United States Department of Health and Urban Services; 2011.
11. Gudala K, Bansal D, Schifano F, Bhansali A,. Diabetes mellitus and risk of dementia: a meta-analysis of prospective observational studies. J Diabetes Investig 2013; 4: 640-50.
12. Cukierman T, Gerstein HC, Williamson JD,. Cognitive decline and dementia in diabetes-systematic overview of prospective observational studies. Diabetologia 2005; 48: 2460-9.
13. Luchsinger JA,. Diabetes, related conditions, and dementia. J Neurol Sci 299: 35-8.
14. Cheng G, Huang C, Deng H, Wang H,. Diabetes as a risk factor for dementia and mild cognitive impairment: a meta-analysis of longitudinal studies. Intern Med J 2012; 42: 484-91.
15. Luchsinger JA, Reitz C, Patel B, Tang M-X, Manly JJ, Mayeux R,. Relation of diabetes to mild cognitive impairment. Arch Neurol 2007; 64: 570-5.
16. Luchsinger JA, Tang MX, Stern Y, Shea S, Mayeux R,. Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol 2001; 154: 635-41.
17. MacKnight C, Rockwood K, Awalt E, McDowell I,. Diabetes mellitus and the risk of dementia, Alzheimer's disease and vascular cognitive impairment in the Canadian Study of Health and Aging. Dement Geriatr Cogn Disord 2002; 14: 77-83.
18. Okereke OI, Kang JH, Cook NR, Gaziano JM, Manson JE, Buring JE, Grodstein F,. Type 2 diabetes mellitus and cognitive decline in two large cohorts of community-dwelling older adults. J Am Geriatr Soc 2008; 56: 1028-36.
19. Velayudhan L, Poppe M, Archer N, Proitsi P, Brown RG, Lovestone S,. Risk of developing dementia in people with diabetes and mild cognitive impairment. Br J Psychiatry 2010; 196: 36-40.
20. Xu W, Caracciolo B, Wang HX, Winblad B, Backman L, Qiu C, Fratiglioni L,. Accelerated progression from mild cognitive impairment to dementia in people with diabetes. Diabetes 2010; 59: 2928-35.
21. Bangen KJ, Gu Y, Gross AL, Schneider BC, Skinner JC, Benitez A, Sachs BC, Shih R, Sisco S, Shupf N, Mayeux R, Manly JJ, Luchsinger JA,. Relation of Type 2 diabetes with cognitive change in a multiethnic elderly cohort. J Am Geriatr Soc. In press.
22. Schneider BC, Gross AL, Bangen KJ, Skinner JC, Benitez A, Glymour MM, Sachs BC, A Shih R, Sisco S, Manly JJ, Luchsinger JA,. Association of vascular risk factors with cognition in a multiethnic sample. J Gerontol B Psychol Sci Soc Sci 2014. Epub ahead of print.
23. Luchsinger JA,. Adiposity, hyperinsulinemia, diabetes and Alzheimer's disease: an epidemiological perspective. Eur J Pharmacol 2008; 585: 119-29.
24. Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, Soininen H, Tuomilehto J, Nissinen A,. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ 2001; 322: 1447-51.
25. Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K,. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 2005; 64: 277-81.
26. Fitzpatrick AL, Kuller LH, Lopez OL, Diehr P, O'Meara ES, Longstreth WT Jr., Luchsinger JA,. Midlife and late-life obesity and the risk of dementia: cardiovascular health study. Arch Neurol 2009; 66: 336-42.
27. Washington Heights/Inwood Demographic, Economic, and Social Transformations 1990-2005 With Special Focus on the Dominican Population. Latino Data Project-Report 18 2008.
28. Standards of medical care in diabetes-2010. Diabetes Care 2010; 33 (suppl 1): S11-61.
29. Summary of revisions for the 2010 clinical practice recommendations. Diabetes Care 2010; 33 (suppl 1): S3.
30. Humes KR, Jones NA, Ramirez RR,. Overview of Race and Hispanic Origin: 2010. Washington, DC: U.S. Department of Commerce, Economic and Statistics Administration; 2011.
31. Biggs ML, Mukamal KJ, Luchsinger JA, Ix JH, Carnethon MR, Newman AB, de Boer IH, Strotmeyer ES, Mozaffarian D, Siscovick DS,. Association between adiposity in midlife and older age and risk of diabetes in older adults. JAMA 303: 2504-12.
32. Luchsinger JA, Cheng D, Tang MX, Schupf N, Mayeux R,. Central obesity in the elderly is related to late-onset Alzheimer disease. Alzheimer Dis Assoc Disord 2012; 26: 101-5.
33. Richard E, Reitz C, Honig LH, Schupf N, Tang MX, Manly JJ, Mayeux R, Devanand D, Luchsinger JA,. Late-life depression, mild cognitive impairment, and dementia. JAMA Neurol 2013; 70: 374-82.
34. March D, Luchsinger JA, Teresi JA, Eimicke JP, Findley SE, Carrasquillo O, Palmas W,. High rates of depressive symptoms in low-income urban Hispanics of Caribbean origin with poorly controlled diabetes: correlates and risk factors. J Health Care Poor Underserved 2014; 25: 321-31.
35. Davidson KW, Kupfer DJ, Bigger JT, Califf RM, Carney RM, Coyne JC, Czajkowski SM, Frank E, Frasure-Smith N, Freedland KE, Froelicher ES, Glassman AH, Katon WJ, Kaufmann PG, Kessler RC, Kraemer HC, Krishnan KR, Lesperance F, Rieckmann N, Sheps DS, Suls JM,. Assessment and treatment of depression in patients with cardiovascular disease: National Heart, Lung, and Blood Institute Working Group Report. Psychosom Med 2006; 68: 645-50.
36. Ridker PM,. Inflammatory biomarkers and risks of myocardial infarction, stroke, diabetes, and total mortality: implications for longevity. Nutr Rev 2007; 65: S253-9.
37. Noble JM, Manly JJ, Schupf N, Tang MX, Mayeux R, Luchsinger JA,. Association of C-reactive protein with cognitive impairment. Arch Neurol 67: 87-92.
38. Goldberg RB, Mather K,. Targeting the consequences of the metabolic syndrome in the Diabetes Prevention Program. Arterioscler Thromb Vasc Biol 2012; 32: 2077-90.
39. Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, Kastelein JJP, Bittner V, Fruchart J-C,. Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007; 357: 1301-10.
40. Ergul A, Kelly-Cobbs A, Abdalla M, Fagan SC,. Cerebrovascular complications of diabetes: focus on stroke. Endocr Metab Immune Disord Drug Targets 2012; 12: 148-58.
41. Exalto LG, Quesenberry CP, Barnes D, Kivipelto M, Biessels GJ, Whitmer RA,. Midlife risk score for the prediction of dementia four decades later. Alzheimers Dement 2014; 10: 562-70.
42. Hachinski V, Iadecola C, Petersen RC, Breteler MM, Nyenhuis DL, Black SE, Powers WJ, DeCarli C, Merino JG, Kalaria RN, Vinters HV, Holtzman DM, Rosenberg GA, Dichgans M, Marler JR, Leblanc GG,. National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke 2006; 37: 2220-41.
43. Small SA, Mayeux R,. A clinical approach to memory decline. J Pract Psychiatry Behav Health 1999; 5: 87-94.
44. Maj M, D'Elia L, Satz P, Janssen R, Zaudig M, Uchiyama C, Starace F, Galderisi S, Chervinsky A,. Evaluation of two new neuropsychological tests designed to minimize cultural bias in the assessment of HIV-1 seropositive persons: a WHO study. Arch Clin Neuropsychol 1993; 8: 123-35.
45. Benton AL,. The Benton Visual Retention Test. New York: Psychological Corp; 1955.
46. Buschke H, Fuld PA,. Evaluating storage, retention, and retrieval in disordered memory and learning. Neurology 1974; 24: 1019-25.
47. Jacobs DM, Sano M, Dooneief G, Marder K, Bell KL, Stern Y,. Neuropsychological detection and characterization of preclinical Alzheimer's disease. Neurology 1995; 45: 957-62.
48. Masur DM, Fuld PA, Blau AD, Crystal H, Aronson MK,. Predicting development of dementia in the elderly with the Selective Reminding Test. J Clin Exp Neuropsychol 1990; 12: 529-38.
49. Masur DM, Sliwinski M, Lipton RB, Blau AD, Crystal HA,. Neuropsychological prediction of dementia and the absence of dementia in healthy elderly persons. Neurology 1994; 44: 1427-32.
50. Luchsinger JA,. A work in progress: the metabolic syndrome. Sci Aging Knowledge Environ 2006; 2006: pe19.
51. Fischer AL, de Frias CM, Yeung SE, Dixon RA,. Short-term longitudinal trends in cognitive performance in older adults with Type 2 diabetes. J Clin Exp Neuropsychol 2009; 31: 809-22.
52. Wu JH, Haan MN, Liang J, Ghosh D, Gonzalez HM, Herman WH,. Impact of diabetes on cognitive function among older Latinos: a population-based cohort study. J Clin Epidemiol 2003; 56: 686-93.
53. van den Berg E, Reijmer YD, de Bresser J, Kessels RP, Kappelle LJ, Biessels GJ,. A 4 year follow-up study of cognitive functioning in patients with Type 2 diabetes mellitus. Diabetologia 2010; 53: 58-65.
54. de Bresser J, Tiehuis AM, van den Berg E, Reijmer YD, Jongen C, Kappelle LJ, Mali WP, Viergever MA, Biessels GJ,. Progression of cerebral atrophy and white matter hyperintensities in patients with Type 2 diabetes. Diabetes Care 2010; 33: 1309-14.
55. Biessels GJ,. Intensive glucose lowering and cognition in Type 2 diabetes. Lancet Neurol 2011; 10: 949-50.
56. Gregg EW, Yaffe K, Cauley JA, Rolka DB, Blackwell TL, Narayan KM, Cummings SR,. Is diabetes associated with cognitive impairment and cognitive decline among older women? Study of Osteoporotic Fractures Research Group. Arch Intern Med 2000; 160: 174-80.
57. Fontbonne A, Berr C, Ducimetiere P, Alperovitch A,. Changes in cognitive abilities over a 4-year period are unfavorably affected in elderly diabetic subjects: results of the Epidemiology of Vascular Aging Study. Diabetes Care 2001; 24: 366-70.
58. Hassing LB, Grant MD, Hofer SM, Pedersen NL, Nilsson SE, Berg S, McClearn G, Johansson B,. Type 2 diabetes mellitus contributes to cognitive decline in old age: a longitudinal population-based study. J Int Neuropsychol Soc 2004; 10: 599-607.
59. Kanaya AM, Barrett-Connor E, Gildengorin G, Yaffe K,. Change in cognitive function by glucose tolerance status in older adults: a 4-year prospective study of the Rancho Bernardo study cohort. Arch Intern Med 2004; 164: 1327-33.
60. Yaffe K, Falvey C, Hamilton N, Schwartz AV, Simonsick EM, Satterfield S, Cauley JA, Rosano C, Launer LJ, Strotmeyer ES, Harris TB,. Diabetes, glucose control, and 9-year cognitive decline among older adults without dementia. Arch Neurol 2012; 69: 1170-5.
61. Euser SM, Sattar N, Witteman JC, Bollen EL, Sijbrands EJ, Hofman A, Perry IJ, Breteler MM, Westendorp RG,. A prospective analysis of elevated fasting glucose levels and cognitive function in older people: results from PROSPER and the Rotterdam Study. Diabetes 2010; 59: 1601-7.
62. Reijmer YD, van den Berg E, Ruis C, Kappelle LJ, Biessels GJ,. Cognitive dysfunction in patients with Type 2 diabetes. Diabetes Metab Res Rev 2010; 26: 507-19.
63. Knopman D, Boland LL, Mosley T, Howard G, Liao D, Szklo M, McGovern P, Folsom AR,. Cardiovascular risk factors and cognitive decline in middle-aged adults. Neurology 2001; 56: 42-8.
64. Biessels GJ, Deary IJ, Ryan CM,. Cognition and diabetes: a lifespan perspective. Lancet Neurol 2008; 7: 184-90.
65. Boden-Albala B, Cammack S, Chong J, Wang C, Wright C, Rundek T, Elkind MS, Paik MC, Sacco RL,. Diabetes, fasting glucose levels, and risk of ischemic stroke and vascular events: findings from the Northern Manhattan Study (NOMAS). Diabetes Care 2008; 31: 1132-7.
66. Treadwell JR,. Pre-diabetes as a contributor to stroke. BMJ 2012; 344: e3285.
67. Lee M, Saver JL, Hong KS, Song S, Chang KH, Ovbiagele B,. Effect of pre-diabetes on future risk of stroke: meta-analysis. BMJ 2012; 344: e3564.
68. Manschot SM, Brands AMA, van der Grond J, Kessels RPC, Algra A, Kappelle LJ, Biessels GJ, Utrecht Diabetic Encephalopathy Study Group. Brain magnetic resonance imaging correlates of impaired cognition in patients with Type 2 diabetes. Diabetes 2006; 55: 1106-13.
69. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR,. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 1997; 277: 813-7.
70. Watson GS, Craft S,. Insulin resistance, inflammation, and cognition in Alzheimer's disease: lessons for multiple sclerosis. J Neurol Sci 2006; 245: 21-33.
71. Watson GS, Craft S,. The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment. CNS Drugs 2003; 17: 27-45.
72. Vekrellis K, Ye Z, Qiu WQ, Walsh D, Hartley D, Chesneau V, Rosner MR, Selkoe DJ,. Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme. J Neurosci 2000; 20: 1657-65.
73. Qiu WQ, Walsh DM, Ye Z, Vekrellis K, Zhang J, Podlisny MB, Rosner MR, Safavi A, Hersh LB, Selkoe DJ,. Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J Biol Chem 1998; 273: 32730-8.
74. Farris W, Mansourian S, Leissring MA, Eckman EA, Bertram L, Eckman CB, Tanzi RE, Selkoe DJ,. Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid {beta}-protein. Am J Pathol 2004; 164: 1425-34.
75. Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP, Eckman CB, Tanzi RE, Selkoe DJ, Guenette S,. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A 2003; 100: 4162-7.
76. Selkoe DJ,. The origins of Alzheimer disease: a is for amyloid. JAMA 2000; 283: 1615-7.
77. Luchsinger JA,. Insulin resistance, Type 2 diabetes, and AD: cerebrovascular disease or neurodegeneration? Neurology 75: 758-9.
78. Arvanitakis Z, Schneider JA, Wilson RS, Li Y, Arnold SE, Wang Z, Bennett DA,. Diabetes is related to cerebral infarction but not to AD pathology in older persons. Neurology 2006; 67: 1960-5.
79. Peila R, Rodriguez BL, Launer LJ, Honolulu-Asia Aging Study. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia Aging Study. Diabetes 2002; 51: 1256-62.
80. Malek-Ahmadi M, Beach T, Obradov A, Sue L, Belden C, Davis K, Walker DG, Lue L, Adem A, Sabbagh MN,. Increased Alzheimer's disease neuropathology is associated with Type 2 diabetes and ApoE ε.4 carrier status. Curr Alzheimer Res 2013; 10: 654-9.
81. Ahtiluoto S, Polvikoski T, Peltonen M, Solomon A, Tuomilehto J, Winblad B, Sulkava R, Kivipelto M,. Diabetes, Alzheimer disease, and vascular dementia: a population-based neuropathologic study. Neurology 2010; 75: 1195-202.
82. Beeri MS, Silverman JM, Davis KL, Marin D, Grossman HZ, Schmeidler J, Purohit DP, Perl DP, Davidson M, Mohs RC, Haroutunian V,. Type 2 diabetes is negatively associated with Alzheimer's disease neuropathology. J Gerontol A Biol Sci Med Sci 2005; 60: 471-5.
83. Bangen KJ, Nation DA, Delano-Wood L, Weissberger GH, Hansen LA, Galasko DR, Salmon DP, Bondi MW,. Aggregate effects of vascular risk factors on cerebrovascular changes in autopsy-confirmed Alzheimer's disease. Alzheimers Dement 2015; 11: 394-403.e1.
84. Chui HC, Zheng L, Reed BR, Vinters HV, Mack WJ,. Vascular risk factors and Alzheimer's disease: are these risk factors for plaques and tangles or for concomitant vascular pathology that increases the likelihood of dementia? An evidence-based review. Alzheimers Res Ther 2012; 4: 1.
85. Maillard P, Carmichael O, Fletcher E, Reed B, Mungas D, DeCarli C,. Coevolution of white matter hyperintensities and cognition in the elderly. Neurology 2012; 79: 442-8.
86. Pugh KG, Kiely DK, Milberg WP, Lipsitz LA,. Selective impairment of frontal-executive cognitive function in African Americans with cardiovascular risk factors. J Am Geriatr Soc 2003; 51: 1439-44.
87. Royall DR, Lauterbach EC, Cummings JL, Reeve A, Rummans TA, Kaufer DI, LaFrance WC Jr., Coffey CE,. Executive control function: a review of its promise and challenges for clinical research. A report from the Committee on Research of the American Neuropsychiatric Association. J Neuropsychiatry Clin Neurosci 2002; 14: 377-405.
88. Small SA, Perera GM, DeLaPaz R, Mayeux R, Stern Y,. Differential regional dysfunction of the hippocampal formation among elderly with memory decline and Alzheimer's disease. Ann Neurol 1999; 45: 466-72.
89. Stern Y,. What is cognitive reserve? Theory and research application of the reserve concept. J Int Neuropsychol Soc 2002; 8: 448-60.
90. Luchsinger JA, Tang M-X, Shea S, Mayeux R,. Hyperinsulinemia and risk of Alzheimer disease. Neurology 2004; 63: 1187-92.
91. Irie F, Fitzpatrick AL, Lopez OL, Kuller LH, Peila R, Newman AB, Launer LJ,. Enhanced risk for Alzheimer disease in persons with Type 2 diabetes and APOE epsilon4: the Cardiovascular Health Study Cognition Study. Arch Neurol 2008; 65: 89-93.
92. Weintraub S, Dikmen SS, Heaton RK, Tulsky DS, Zelazo PD, Bauer PJ, Carlozzi NE, Slotkin J, Blitz D, Wallner-Allen K, Fox NA, Beaumont JL, Mungas D, Nowinski CJ, Richler J, Deocampo JA, Anderson JE, Manly JJ, Borosh B, Havlik R, Conway K, Edwards E, Freund L, King JW, Moy C, Witt E, Gershon RC,. Cognition assessment using the NIH toolbox. Neurology 2013; 80: S54-64.
93. Selhub J, Jacques PF, Bostom AG, D'Agostino RB, Wilson PW, Belanger AJ, O'Leary DH, Wolf PA, Schaefer EJ, Rosenberg IH,. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med 1995; 332: 286-91.
94. Olson DE, Rhee MK, Herrick K, Ziemer DC, Twombly JG, Phillips LS,. Screening for diabetes and pre-diabetes with proposed A1C-based diagnostic criteria. Diabetes Care 2010; 33: 2184-9.
95. Cowie CC, Rust KF, Ford ES, Eberhardt MS, Byrd-Holt DD, Li C, Williams DE, Gregg EW, Bainbridge KE, Saydah SH, Geiss LS,. Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-1994 and 2005-2006. Diabetes Care 2009; 32: 287-94.
96. Gregg EW, Zhuo X, Cheng YJ, Albright AL, Narayan KM, Thompson TJ,. Trends in lifetime risk and years of life lost due to diabetes in the USA, 1985-2011: a modelling study. Lancet Diabetes Endocrinol 2014; 2: 867-74.
97. Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR, Wiedmeyer HM, Byrd-Holt DD,. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 1998; 21: 518-24.
98. Luchsinger JA,. Diabetes. In: Aguirre-Molina M, Molina CW, Zambrana RE, editors. Health Issues in the Latino Community. San Francisco: Jossey-Bass; 2001; 277-300.